Jazz Pharma Highlights Groundbreaking Sleep Research at SLEEP 2024

Jazz Pharmaceuticals will present thirteen abstracts at the SLEEP 2024 conference, highlighting their ongoing dedication to improving the understanding and treatment of sleep disorders. This event, organized by the Associated Professional Sleep Societies, will take place from June 1-5, 2024, in Houston, Texas. Among the presentations, five are late-breaking abstracts, underscoring new data from Jazz's sleep medicine portfolio.

One key presentation will be an oral discussion on the Phase 4 XYLO study design, which evaluates changes in 24-hour average systolic blood pressure in patients with narcolepsy switching from a high-sodium to low-sodium oxybate solution, specifically Xywav®. Another oral presentation will analyze the efficacy and safety of Xywav in patients with narcolepsy, both with and without psychiatric and neurological comorbidities, showing comparable results in both groups.

Kelvin Tan, Senior Vice President and Chief Medical Officer of Jazz Pharmaceuticals, expressed pride in the range of data being presented, emphasizing the company's commitment to addressing unmet needs in the sleep disorder community. For nearly two decades, Jazz Pharmaceuticals has focused on delivering patient-centric solutions for conditions like narcolepsy and idiopathic hypersomnia.

Key highlights of the presentations at SLEEP 2024 include:

1. Two late-breaking poster presentations using data from the U.S. National Health and Wellness Survey to assess the burden of idiopathic hypersomnia. One analysis highlighted the substantial comorbidity and quality-of-life impact on U.S. adults with this condition, while the other revealed significant economic burdens, including decreased work productivity.

2. Four posters, two of which are late-breaking abstracts, detailing the design and participant baseline characteristics from the DUET study—a Phase 4, prospective study evaluating the effects of Xywav on excessive daytime sleepiness and other outcomes in adults with idiopathic hypersomnia or narcolepsy.

3. A poster presenting a Phase 3 trial post-hoc analysis demonstrating that Xywav maintains its efficacy and safety in narcoleptic patients, irrespective of the presence of cardiovascular or cardiometabolic comorbidities.

Narcolepsy is a chronic sleep disorder characterized by excessive daytime sleepiness (EDS) and an inability to regulate sleep-wake cycles, often leading to unplanned lapses into sleep. It significantly impacts patients' social, psychological, and professional lives and is linked to elevated risks for cardiovascular and metabolic conditions. Early access to low-sodium treatments like Xywav could improve the physical and mental health of people living with this lifelong condition.

Idiopathic hypersomnia is another serious, chronic neurologic sleep disorder marked by excessive daytime sleepiness, long and non-restorative sleep episodes, cognitive impairment, and severe sleep inertia. It severely affects social, educational, and occupational functioning. Approximately 37,000 adults in the U.S. seek healthcare for idiopathic hypersomnia, though fewer receive appropriate pharmacological treatment due to diagnostic challenges.

Xywav, a low-sodium oxybate solution, has been approved by the U.S. FDA for treating cataplexy or EDS in patients with narcolepsy aged seven and older, as well as for idiopathic hypersomnia in adults. Xywav's unique composition reduces sodium intake significantly compared to traditional treatments, offering a safer cardiovascular profile. The drug is available through a strictly regulated program to mitigate risks associated with CNS depression and misuse.

The SLEEP 2024 conference will provide a platform for Jazz Pharmaceuticals to showcase their advancements in sleep medicine, reflecting their ongoing efforts to address the complexities and burdens of sleep disorders.